301 related articles for article (PubMed ID: 24470514)
21. Immunotherapy in Lung Cancer: From a Minor God to the Olympus.
Russo A; McCusker MG; Scilla KA; Arensmeyer KE; Mehra R; Adamo V; Rolfo C
Adv Exp Med Biol; 2020; 1244():69-92. PubMed ID: 32301011
[TBL] [Abstract][Full Text] [Related]
22. Immune-based Therapies for Non-small Cell Lung Cancer.
Rafei H; El-Bahesh E; Finianos A; Nassereddine S; Tabbara I
Anticancer Res; 2017 Feb; 37(2):377-387. PubMed ID: 28179283
[TBL] [Abstract][Full Text] [Related]
23. Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy.
Carbone DP; Gandara DR; Antonia SJ; Zielinski C; Paz-Ares L
J Thorac Oncol; 2015 Jul; 10(7):974-84. PubMed ID: 26134219
[TBL] [Abstract][Full Text] [Related]
24. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.
Pennell NA
Semin Oncol; 2015 Oct; 42 Suppl 2():S3-10. PubMed ID: 26477472
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy and lung cancer: current developments and novel targeted therapies.
Domingues D; Turner A; Silva MD; Marques DS; Mellidez JC; Wannesson L; Mountzios G; de Mello RA
Immunotherapy; 2014; 6(11):1221-35. PubMed ID: 25496336
[TBL] [Abstract][Full Text] [Related]
26. Selecting patients for immune checkpoint inhibition in lung cancer.
Garon EB
Clin Adv Hematol Oncol; 2015 Aug; 13(8):490-2. PubMed ID: 26351808
[No Abstract] [Full Text] [Related]
27. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience.
Mellstedt H; Vansteenkiste J; Thatcher N
Lung Cancer; 2011 Jul; 73(1):11-7. PubMed ID: 21474197
[TBL] [Abstract][Full Text] [Related]
28. MAGE A3 antigen-specific cancer immunotherapeutic.
Peled N; Oton AB; Hirsch FR; Bunn P
Immunotherapy; 2009 Jan; 1(1):19-25. PubMed ID: 20635969
[TBL] [Abstract][Full Text] [Related]
29. Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives.
Rice SJ; Miller B; Wagman M; Jamorabo DS; Liu X; Belani CP
Curr Mol Pharmacol; 2016; 9(3):183-195. PubMed ID: 26177648
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy in non-small-cell lung cancer: from targeted molecules to resistance patterns.
Brassart-Pasco S; Dalstein V; Brassart B; Dewolf M; Clavel C; Oudart JB
Pharmacogenomics; 2020 Jul; 21(10):705-720. PubMed ID: 32567537
[TBL] [Abstract][Full Text] [Related]
31. PD-1-targeted immunotherapy: recent clinical findings.
Brahmer JR
Clin Adv Hematol Oncol; 2012 Oct; 10(10):674-5. PubMed ID: 23187774
[No Abstract] [Full Text] [Related]
32. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer.
Aerts JG; Hegmans JP
Cancer Res; 2013 Apr; 73(8):2381-8. PubMed ID: 23580578
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy in the treatment of non-small cell lung cancer.
Sundar R; Soong R; Cho BC; Brahmer JR; Soo RA
Lung Cancer; 2014 Aug; 85(2):101-9. PubMed ID: 24880938
[TBL] [Abstract][Full Text] [Related]
34. Novel targeted agents for lung cancer.
West HJ
Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S41-6. PubMed ID: 19362946
[TBL] [Abstract][Full Text] [Related]
35. Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?
Gardiner RE; Jahangeer S; Forde P; Ariffin AB; Bird B; Soden D; Hinchion J
Cancer Metastasis Rev; 2015 Mar; 34(1):129-44. PubMed ID: 25726003
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy in non-small-cell lung carcinoma: from inflammation to vaccination.
Van den Heuvel MM; Burgers SA; van Zandwijk N
Clin Lung Cancer; 2009 Mar; 10(2):99-105. PubMed ID: 19362952
[TBL] [Abstract][Full Text] [Related]
37. Emepepimut-S for non-small cell lung cancer.
Corrales-Rodriguez L; Blais N; Soulières D
Expert Opin Biol Ther; 2011 Aug; 11(8):1091-7. PubMed ID: 21689064
[TBL] [Abstract][Full Text] [Related]
38. Emerging drugs targeting PD-1 and PD-L1: reality or hope?
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Expert Opin Emerg Drugs; 2014 Dec; 19(4):557-69. PubMed ID: 25253438
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.
Zheng H; Zeltsman M; Zauderer MG; Eguchi T; Vaghjiani RG; Adusumilli PS
Immunotherapy; 2017 Sep; 9(11):913-927. PubMed ID: 29338609
[TBL] [Abstract][Full Text] [Related]
40. The immunotherapeutic landscape in non-small cell lung cancer and its surgical horizons.
Rhodin KE; Rucker AJ; Ready NE; D'Amico TA; Antonia SJ
J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1616-1623. PubMed ID: 31836182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
